- Home
- BSBK vs CUE Comparison
BSBK vs CUE Comparison
Compare BSBK & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSBK | CUE |
|---|---|---|
| Founded | 1893 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.0M | 124.5M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BSBK | CUE |
|---|---|---|
| Price | $9.06 | $28.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 8.8K | ★ 76.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 200.00 | 61.11 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $151.00 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $7.90 | $0.17 |
| 52 Week High | $9.49 | $41.42 |
Technical Indicators
Market Signals| Indicator | BSBK | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 53.98 |
| Support Level | $8.83 | $0.24 |
| Resistance Level | $9.29 | $32.82 |
| Average True Range (ATR) | 0.12 | 3.73 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 62.50 | 42.89 |
Price Performance
Historical ComparisonAbout BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from, customers in New Jersey. The Company operates one reportable segment of business, retail banking. Through its community banking segment, the Company provides a broad range of retail and commercial banking services.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.